Blog
Developing Psychedelics for Use in CNS Disorders
An expanding body of research suggesting that psychedelics could treat CNS disorders like substance abuse, depression, chronic pain, and schizophrenia has sparked a renewed interest in recent years by drug developers and investors.
VeraSci Partners with Aural Analytics to Incorporate Speech Analytics into Pathway eCOA Platform
VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with Aural Analytics, Inc., a global leader in speech analytics for clinical research....
A Transdiagnostic Approach Could Change Drug Development for CNS Disorders
Most products being developed today for CNS diseases and disorders are under development for a specific indication like depression, Parkinson’s disease, or schizophrenia. This approach focuses on obtaining approval to treat patients with a specific diagnosis and...
Examining the Connection Between COVID-19 and Cognition
Increasing evidence is emerging that cognitive symptoms persist well beyond the acute phase of COVID-19 illness and well after patients have cleared the virus.
VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials
Durham, NC—January 19, 2021—VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is pleased to announce a new partnership with ActiGraph, a leading provider of medical-grade wearable...
VeraSci Sees Continued Growth Despite COVID-19 Challenges Faced by Clinical Trials Industry
Durham, NC—December 18, 2020—VeraSci—a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments—is concluding a successful year marked by extensive hiring and expanded service offerings. This growth...
Study Supporting Effectiveness of the Placebo-Control Reminder Script (PCRS) Published in Neuropsychopharmacology
Neuropsychopharmacology recently published “Placebo Response Mitigation with a Participant-Focused Psychoeducational Procedure: A Randomized, Single-Blind, All Placebo Study in Major Depressive and Psychotic Disorders”. Dr. Bill Horan, Vice President Clinical Science...
Innovation Lab Releases Preliminary Findings in Wearables Study
This blog series shares what’s happening day-to-day in our Innovation Lab. VeraSci created the Innovation Lab to pair scientific knowledge with cutting-edge technology to improve the tools and measurements available for clinical trials. We originally presented these...
Regulatory Challenges in Pediatric Drug Development: The European Perspective
Dr. Luca Pani is the former Director General of the Italian Medicines Agency and a former member of the Board of Directors of the Committee...
Using eCOA to Improve Data Quality in Parkinson’s Disease Clinical Trials
One of the most frequently used assessments in clinical trials of Parkinson’s Disease is the Movement Disorders Society version of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Producing high-quality data is crucial for demonstrating efficacy for new...